Metabolic Disorders

Transforming endocrine and metabolic care

Endocrine & Metabolic Research

SXR Laboratories conducts trials for diabetes, obesity, thyroid disorders, and other metabolic conditions. We specialize in complex metabolic endpoint assessments and long-term outcome studies.

Research Focus

Type 1 and Type 2 diabetes trials
Obesity and weight management
Thyroid disorder studies
NASH and liver disease
Lipid metabolism research
Rare metabolic diseases

Foundational Technologies & Key Targets

Molecular Targets

GLP-1 Receptor: Glucagon-like peptide-1 receptor, targeted by agonists for diabetes and obesity management, improving insulin secretion and reducing appetite.

PPAR Receptors: Peroxisome proliferator-activated receptors involved in glucose and lipid metabolism regulation.

Metabolic Enzymes: Various enzymes involved in rare inborn errors of metabolism (e.g., PAH in Phenylketonuria, alpha-GAL in Fabry disease).

Therapeutic Approaches

GLP-1 Agonists: Injectable medications (semaglutide, tirzepatide) for diabetes and obesity, revolutionizing metabolic disease treatment. SGLT2 Inhibitors: Oral medications promoting glucose excretion through kidneys. Enzyme Replacement Therapy (ERT): Providing missing enzymes for lysosomal storage diseases like Gaucher and Fabry diseases.

Gene Therapy Applications

AAV-Mediated Enzyme Delivery: Using adeno-associated virus vectors to deliver functional genes for rare metabolic disorders like Phenylketonuria (PKU) and Fabry disease.
mRNA Therapy: Delivering temporary enzyme replacement via mRNA for metabolic enzyme deficiencies.
Gene Editing: Exploring CRISPR correction of metabolic enzyme genes for permanent therapeutic effect.

Comprehensive Assessment

We utilize continuous glucose monitoring, metabolic profiling, body composition analysis, and cardiovascular outcome assessments for thorough evaluation of metabolic interventions.

Integrated Research Excellence

Metabolic research requires long-term coordination of complex endpoints across multiple systems. Clinical Trials Management implements studies with continuous glucose monitoring, DEXA scans, and cardiovascular outcomes assessment over extended periods. Data Management captures intricate metabolic profiling data, laboratory values, and device-generated glucose data streams. Biostatistics analyzes longitudinal metabolic data with mixed-effects models and cardiovascular safety assessments. Quality Assurance ensures accuracy of metabolic measurements and laboratory standardization. Regulatory Affairs navigates metabolic disease regulatory pathways, and Medical Writing synthesizes complex metabolic and cardiovascular data into cohesive regulatory narratives.